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AbstrACt
Introduction Postoperative pulmonary complications 
(PPCs) are a common serious complication following 
upper abdominal surgery leading to significant 
consequences including increased mortality, hospital 
costs and prolonged hospitalisation. The primary 
objective of this study is to detect whether there is a 
possible signal towards PPC reduction with the use 
of additional intermittent non-invasive ventilation 
(NIV) compared with continuous high-flow nasal 
oxygen therapy alone following high-risk elective 
upper abdominal surgery. Secondary objectives are 
to measure feasibility of: (1) trial conduct and design 
and (2) physiotherapy-led NIV and a high-flow nasal 
oxygen therapy protocol, safety of NIV and to provide 
preliminary costs of care information of NIV and high-
flow nasal oxygen therapy.
Methods and analysis This is a single-centre, 
parallel group, assessor blinded, pilot, randomised 
trial, with 130 high-risk upper abdominal surgery 
patients randomly assigned via concealed allocation 
to either (1) usual care of continuous high-flow nasal 
oxygen therapy for 48 hours following extubation 
or (2) usual care plus five additional 30 min 
physiotherapy-led NIV sessions within the first two 
postoperative days. Both groups receive standardised 
preoperative physiotherapy and postoperative early 
ambulation. No additional respiratory physiotherapy 
is provided to either group. Outcome measures 
will assess incidence of PPC within the first 14 
postoperative days, recruitment ability, physiotherapy-
led NIV and high-flow nasal oxygen therapy protocol 
adherence, adverse events relating to NIV delivery and 
costs of providing a physiotherapy-led NIV and a high-
flow nasal oxygen therapy service following upper 
abdominal surgery.
Ethics and dissemination Ethics approval has been 
obtained from the relevant institution and results will 
be published to inform future multicentre trials.
trial registration number ACTRN12617000269336; Pre-
results.
IntroduCtIon 
Postoperative pulmonary complications 
(PPCs) are a common serious complication 
following upper abdominal surgery with a 
reported incidence of 13%–42%.1–6 Devel-
opment of a PPC is strongly associated with 
increased postoperative mortality, morbidity 
and prolonged hospitalisation.2 3 7 
There are well-reported pathophysiological 
effects of anaesthesia and upper abdominal 
surgery on the respiratory system including 
prolonged lung volume reductions, 
diaphragm dysfunction, alveolar collapse 
and reduced mucociliary clearance.8 9 The 
combination of which establishes a patho-
logical environment for bacterial growth and 
impaired pulmonary gas exchange, which 
can lead to postoperative respiratory failure 
and/or pneumonia.10 11
Following surgery, respiratory optimisation 
and support is warranted to avoid respira-
tory failure and subsequent reintubation.12 
strengths and limitations of this study
 ► This pilot study is a 130-patient parallel group ran-
domised clinical trial of additional early intermittent
postoperative non-invasive ventilation (NIV) versus
continuous high-flow nasal oxygen therapy alone.
 ► This trial is measuring recruitment ability and feasi-
bility of providing physiotherapy-led NIV and a high-
flow nasal oxygen therapy protocol.
 ► This trial standardises physiotherapy and postoper-
ative ambulation.
 ► This is a pilot, single-centre study unlikely to be
powered to determine treatment effectiveness.
 ► Results of this pilot study will assist the design and
conduct of future definitive multicentre trials.
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Conventional low-flow oxygen therapy is commonly 
administrated via nasal cannula or a face mask to supple-
ment oxygenation yet may not be effective to compensate 
for loss of lung volume.13 While oxygen support alone 
may be sufficient for low-risk patients in the postoperative 
period, increased attention to patients at high-risk of PPC 
development to provide additional therapies that aim to 
increase postoperative lung volumes may be warranted.
Non-invasive ventilation (NIV) has been shown to 
reverse reduced lung volumes induced by anaesthesia 
and abdominal surgery.11 During NIV, the positive airway 
pressure throughout the breath cycle may reopen atel-
ectatic alveoli, increase lung volume and improve gas 
exchange.11 Postoperative NIV has been reported to 
reduce PPC by half, with a further significant subgroup 
effect specifically for preventing pneumonia14–17 following 
upper abdominal surgery. While the optimal preventative 
NIV intervention dosage parameters are currently unde-
termined, the timing of postoperative NIV initiation is 
argued to have an important influence on its effectiveness 
with earlier application of NIV thought to lead to more 
successful alveolar recruitment.18–20 Despite relatively 
good evidence supporting the use of NIV in the early 
postoperative period to reduce PPC, the implementation 
of broad-scale routine prophylactic NIV use is currently 
unclear but appears to be limited.4 21 The reasons for 
which are unknown yet likely multifactorial, including 
perceived risks, resources required and associated service 
costs. It is possible that newer modalities such as high-flow 
nasal oxygen therapy could be a viable and more feasible 
alternative than preventative NIV to reduce PPC.
High-flow nasal oxygen therapy delivers heated and 
humidified oxygen and/or air via nasal prongs at a 
prescribed accurate fraction of inspired oxygen (FiO2) 
and with a maximum flow rate of 60 litres per minute. This 
constant high gas flow at the nares creates a flow-depen-
dent, low level of positive airway pressure between 5 cmH2 
O and 8 cmH2O.
22 23 It is hypothesised that this low level
of positive pressure increases lung volumes and improves 
oxygenation24 25 and may potentially decrease the inci-
dence of respiratory complications post extubation and 
post surgery.26 Compared with standard oxygen therapy, 
high-flow nasal oxygen therapy reduces reintubation 
rates and desaturation episodes in critically ill intensive 
care unit (ICU) patients with acute respiratory failure27 
and reduces the requirement for escalation of respiratory 
support following cardiac surgery.28 When compared with 
NIV, high-flow nasal oxygen therapy provided to prevent 
intubation was superior in reducing 90-day morality in 
patients with acute respiratory failure in ICU.29 Following 
cardiothoracic surgery, high-flow nasal oxygen therapy 
demonstrated equivalence with NIV in reducing post-
surgery reintubation in patients who developed respira-
tory failure or were deemed at risk of respiratory failure 
following postsurgical extubation.30
Following major abdominal surgery, it is possible that 
high-flow nasal oxygen therapy may assist in preventing 
PPCs. It could be just as effective as NIV and potentially 
more feasible in terms of resources required and service 
costs. This has yet to be established as all previous NIV 
clinical trials14 17 investigating the prevention of PPC 
following abdominal surgery have compared NIV wit 
standard oxygen therapy alone, never to high-flow nasal 
oxygen therapy. A recent large multicentre randomised 
control trial (RCT) (Optiflow for prevention of post-ex-
tubation hypoxemia after abdominal surgery (OPERA) 
trial)31 demonstrated no benefit in preventing hypox-
aemia following major abdominal surgery with the use 
of preventative high-flow nasal oxygen therapy compared 
with standard oxygen therapy. Participants were provided 
with high-flow nasal oxygen therapy postoperatively for a 
median duration of 15 (IQR 12–18) hours following extu-
bation.31 As postoperative respiratory failure commonly 
occurs within 72 hours after surgery32 and functional 
residual capacity is shown to reach its lowest value 1–2 days 
following upper abdominal surgery,33–35 it may be that 
high-flow nasal oxygen therapy needs to be prescribed for 
a longer duration to be clinically effective in preventing 
PPCs in the postoperative period. It has been recom-
mended that the utility of postoperative high-flow nasal 
oxygen therapy in high-risk patients when used for longer 
durations be explored.36
Due to the growing exploratory evidence supporting 
the theoretical and proposed clinical benefits of high-flow 
nasal oxygen therapy,37 38 clinical uptake has increased,39 
and the application of high-flow nasal oxygen therapy 
is becoming widespread in ICUs40 including at our own 
institution41 and also in other clinical settings including 
the ward.42 Given this increasing use of high-flow nasal 
oxygen therapy yet uncertainty regarding the preventa-
tive properties, increased reported patient comfort/toler-
ance compared with NIV43 and unknown comparative 
costs of providing a NIV and/or high-flow nasal oxygen 
therapy service to high-risk upper abdominal surgery 
patients, this study is designed to detect whether there is 
a possible signal towards reduction in PPC with the use 
of intermittent NIV in addition to continuous high-flow 
oxygen therapy in the first 48 hours after surgery and 
measure the feasibility of providing these interventions. 
This study is also designed to understand the associated 
costs of service delivery for both these therapies. These 
findings will assist in designing and conducting future 
multicentre trials.
Pilot work
Prior to commencing this pilot RCT, we undertook an 
observational study to test the feasibility and safety of inter-
mittent physiotherapy-led NIV following high-risk elective 
upper abdominal surgery.41 While physiotherapy-led NIV 
was able to be delivered within 24 hours following surgery 
and was shown to be safe in both ICU and ward patients,41 
the main barrier identified to early postoperative NIV was 
physiotherapy service-related limitations.41 Due to lengthy 
surgeries, a large proportion of patients did not return to 
the ward or ICU until after our hospital’s standard phys-
iotherapy working hours. These patients missed receiving 
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the planned initial NIV dose within the target 4 hours. On 
average, our patients received their first NIV session at 
18 hours postsurgery. To mitigate this problem, we imple-
mented a flexible-hour physiotherapy NIV service in the 
immediate postanaesthesia care unit (PACU), also known 
as the recovery room. Providing NIV in the PACU has 
been reported to be feasible and safe.44
objectives
This project is a pilot RCT with the aim of planning a 
future definitive multicentre RCT to compare the use of 
additional intermittent physiotherapy-led NIV to contin-
uous high-flow nasal oxygen therapy alone following 
elective high-risk upper abdominal surgery to reduce 
PPC incidence. The primary objective of this pilot study 
is to detect whether there is a possible signal towards 
PPC reduction with additional NIV compared with high-
flow nasal oxygen therapy. Secondary objectives are to 
measure the feasibility of: (1) trial conduct and design 
and (2) physiotherapy-led NIV and a high-flow nasal 
oxygen therapy protocol, safety of NIV therapy and to 
provide preliminary costs of care information on NIV and 
high-flow nasal oxygen therapy following upper abdom-
inal surgery. In addition, this trial will explore possible 
effects on postsurgical ICU and hospital length of stay 
(LOS); unplanned ICU admission at any time-point 
during the acute postsurgical stay; incidence of reintuba-
tion; in-hospital, 30-day and 12-month all-cause mortality; 
and health-related quality of life (HRQoL). As this study 
is a pilot, there is no formal hypothesis.
MEthods
design
The Non-Invasive Positive airway Pressure therapy to 
Reduce Postoperative Lung complications following 
Upper abdominal Surgery (NIPPER PLUS) trial is a 
prospective, single-centre, assessor blinded, parallel 
group, pilot, randomised controlled trial, with patients 
randomly assigned via concealed allocation to either 
usual care (continuous high-flow nasal oxygen therapy 
for the first 48 hours after surgery and early standardised 
mobilisation) or intervention (usual care plus five 30 min 
NIV sessions). Figure 1 outlines the schedule of enrol-
ment, interventions and assessments. Randomisation is 
stratified to planned postsurgical destination (ward or 
high dependency unit (HDU)/ICU). See figure 2 for a 
Consolidated Standards of Reporting Trials diagram of 
the NIPPER PLUS trial and table 1 for an overview of the 
trial methods and design. The methods are reported in 
accordance with the Standard Protocol Items; Recom-
mendations for Interventional Trials45 guidelines for clin-
ical trials and the Template for Intervention Description 
and Replication46 for reporting of interventions.
Patient and public involvement
There was no involvement from patients or the public in 
the development or the design of this trial.
setting
The NIPPER PLUS trial is being undertaken at a large 
regional primary referral publicly funded hospital in 
Australia. 
Participants and enrolment
All patients having major surgery at our hospital are 
required to attend a preadmission assessment clinic 
within 6 weeks of surgery. At this clinic, any patient listed 
for elective major abdominal surgery receives respiratory 
physiotherapy education on the prevention of PPC and 
breathing exercise training.47 For the NIPPER PLUS trial, 
all patients are screened by the preoperative physiother-
apist using the Melbourne Risk Prediction Tool (MRPT)6 
to determine if they are at high risk of developing a PPC. 
These patients, and any patient with a planned postop-
erative admission to ICU or HDU, are invited by the 
preoperative physiotherapist to participate in the trial. 
Eligible patients are provided with a verbal explanation 
of the trial and provision of written and pictorial informa-
tion. Consenting patients are required to sign a written 
consent form. Where the preoperative physiotherapist or 
the eligible patient is unable to attend the preadmission 
clinic, the patient is contacted by telephone and invited 
to enter the trial. The consent form is then signed during 
their hospital admission. Participant recruitment began 
in March 2017 and aims to be completed by August 2018, 
with final follow-up to be August 2019.
Eligibility criteria
Inclusions
Eligible participants are patients meeting the following 
criteria:
1. Adults (≥18 years) undergoing elective upper abdom-
inal surgery, able to understand verbal instructions in
English and provide informed consent.
2. Open and/or hand-assisted laparoscopic upper ab-
dominal surgery with an abdominal incision longer
than 5 cm that is above or extending above the umbi-
licus.
3. At high-risk of PPC defined in hierarchal order: (1) a
planned postsurgical admission to ICU/HDU and (2)
Identified at high-risk using the MRPT.6
Exclusions
The following exclusion criteria apply:
1. Pre-existing obstructive sleep apnoea where overnight
continuous positive airway pressure is required.
2. Extreme claustrophobia and inability to tolerate use of
a NIV face mask.
3. Current hospital patient for a separate episode of care.
4. Patients requiring oesophageal surgery or organ trans-
plant.
5. Any absolute contraindications for NIV in the period
following surgery prior to first NIV session (table 2).
randomisation and allocation
A research assistant independent to the trial prepre-
pared 130 sequentially numbered (1–130) opaque 
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envelopes each containing an allocation card wrapped 
in aluminium foil. Allocation sequence is generated by a 
web-based computer program (http://www. randomizer. 
org/). Random allocation is stratified to planned postsur-
gical destination (ICU and ward). One of the aims of this 
study is the feasibility of high-flow nasal oxygen therapy 
and NIV application. The ease of application could be 
biased towards it being more or less feasible in one loca-
tion over another. Stratification ensures that there will be 
equal representation of participants at both locations. At 
our centre, historical data find that approximately 70% 
of high-risk upper abdominal surgery patients have a 
planned postoperative ICU admission. To manage this 
difference in location distribution, the total sample size 
of 130 is divided into two blocks with 90 in the ICU block 
and 40 in the ward block. The allocation sequence in 
each block is then determined in a 1:1 ratio, control and 
intervention. Following construction of the randomisa-
tion envelopes, the allocation sequence is locked securely 
in the hospital’s research institute and unavailable to site 
investigators, those who enrol participants and/or assign 
interventions.
If it arises that the ratio of eligible ward or ICU patients 
is different than previously ascertained this will mean that 
one of the blocks (two blocks stratified to location: ICU 
or ward) of envelopes will become exhausted prior to 
completion of the trial. If this occurs, the next available 
envelope for the other intended postoperative location 
(ICU or ward), regardless of the actual postoperative 
location, will be opened in sequence and so on until the 
minimum target sample of 130 is met. If the situation 
occurs where the minimum sample is achieved prior to 
the completion of the funded time period (see sample 
size section), a block of non-stratified allocation opaque 
Figure 1 NIPPER PLUS participant timeline and schedule of events. D/C, discharge; HRQoL, health-related quality of life; ICU, 
intensive care unit; LOS, length of stay; NIPPER PLUS, Non-Invasive Positive airway Pressure therapy to Reduce Postoperative 
Lung complications following Upper abdominal Surgery; NIV, non-invasive ventilation; POD, postoperative day; PPC, 
postoperative pulmonary complication.
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sealed envelopes will be constructed by an indepen-
dent administration assistant using the same web-based 
computer randomisation programme at a 1:1 ratio 
(control:intervention) in a single block of 15, and then 
repeated as necessary until trial completion.
Entry into the trial is finalised at the end of the 
surgical procedure where the postsurgical destination 
is confirmed and exclusion criteria is assessed. Eligible 
consenting patients are then randomised into the trial 
by the lead or a site investigator only by opening the 
next sequentially numbered sealed opaque envelope 
according to the patient’s planned postsurgical destina-
tion (ward or ICU/HDU). Once opened, participant’s 
details are written on the envelope to ensure that patients 
were randomised in presenting order and these are filed 
securely along with the signed consent form. If a patient 
is identified as ineligible following surgery completion, 
they will not be randomised nor entered into the trial. 
Participants are randomly assigned to receive either (1) 
continuous high-flow nasal oxygen therapy for 48 hours 
following extubation (control group) or (2) continuous 
high-flow nasal oxygen therapy for 48 hours following 
extubation plus five 30 min sessions of NIV implemented 
by a physiotherapist over the first two postoperative days 
(intervention group).
Interventions
Control group (usual care)
All participants receive preoperative respiratory phys-
iotherapy education and training.47 Postoperatively, an 
early ambulation programme is provided as per a stan-
dardised protocol48 of once daily physiotherapy-directed 
assisted ambulation (table 3). Participants are provided 
with early ambulation until a threshold score is met 
using a criteria-lead scoring tool,49 or until discharged 
from hospital, whichever occurs first. If a participant is 
Figure 2 CONSORT flow diagram for the NIPPER PLUS study. CONSORT, Consolidated Standards of Reporting Trials; 
HRQoL, health-related quality of life; NIPPER PLUS, Non-Invasive Positive airway Pressure therapy to Reduce Postoperative 
Lung complications following Upper abdominal Surgery; NIV, non-invasive ventilation; POD, postoperative day; PPC, 
postoperative pulmonary complication.
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referred for a mobility review, progression of gait aid 
or a stairs assessment following discharge from physio-
therapy, the participant will be treated at the discretion 
of the ward physiotherapist and this occasion of service 
recorded. Following surgery, no respiratory physio-
therapy is provided to either group unless the participant 
develops the primary endpoint - a PPC, physiotherapy 
will then be provided at the discretion of the attending 
physiotherapist. The type of treatment/s provided will be 
documented.
On the day of surgery, a site investigator documents 
high-flow nasal oxygen therapy orders on each consenting 
patient’s postanaesthetic observation chart to instruct 
theatre nursing staff to initiate high-flow nasal oxygen 
Table 1 Trial registration data set for NIPPER PLUS trial
Data category Information
Primary registry and trial identifying 
number
Australian New Zealand Clinical Trials Registry number: ACTRN12617000269336
Date of registration in primary registry 22/02/2017
Secondary identifying numbers n/a
Trial protocol version This is version 2 of the protocol and was enacted on February 2017.
Source of monetary or material support Clifford Craig Foundation ($A80 000)
Contact for public queries JL: jane.lockstone@ths.tas.gov.au
Contact for scientific queries JL: jane.lockstone@ths.tas.gov.au
Public title Does early postoperative non-invasive ventilation (NIV) prevent chest infections 
following high-risk elective abdominal surgery
Scientific title NIPPER-PLUS trial – Non-Invasive Positive airway Pressure therapy to Reduce 
Postoperative Lung Complications following Upper abdominal Surgery: a single 
centre pilot randomised control trial
Countries of recruitment Australia
Health condition(s) or problem(s) 
studied Intervention(s)
Pulmonary complications following high-risk elective upper abdominal surgery.
Active comparator: physiotherapy-led postoperative NIV therapy.
Placebo comparator: high-flow nasal prong oxygen therapy.
Key inclusion and exclusion criteria Ages edible for study: ≥18 years.
Sexes eligible for study: both.
Accepts health volunteers: no.
Inclusion criteria: all adults undergoing high-risk elective open and/or advanced 
hand-assisted laparoscopic abdominal surgery.
Exclusion criteria: (1) any absolute contraindications for NIV in the period following 
surgery prior to the first NIV session; (2) oesophageal surgery; (3) obstructive 
sleep apnoea requiring continuous positive airway pressure overnight; (4) extreme 
claustrophobia; (5) not able to understand verbal instructions in English; (6) do not 
have capacity to give consent themselves; (7) a current hospital patient for a separate 
episode of care; and (8) requiring organ transplant.
Study type Type: investigator initiated, interventional, non-pharmacological, pilot study.
Allocation: concealed randomisation.
Intervention model: parallel assignment.
Masking: assessor blinding.
Primary purpose: prevention.
Phase: phase 2.
Date of first enrolment 23/02/2017
Target sample size Minimum 130
Recruitment status Recruiting
Primary Outcome Postoperative pulmonary complication during the first 14 postoperative days.
Key secondary outcomes Recruitment ability, physiotherapy-led NIV and high-flow nasal oxygen therapy 
protocol adherence, safety of NIV therapy, associated costs of high-flow nasal 
oxygen therapy and a physiotherapy-led NIV service following upper abdominal 
surgery. In addition, this study will explore effects on incidence of pneumonia; 
intensive care unit (ICU) and hospital length of hospital; ICU readmission rates; 
incidence of reintubation; in-hospital, 30-day and 12-month all-cause mortality; and 
health related quality of life.
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therapy as soon as possible following extubation. These 
orders specify that the FiO2 is to be titrated to achieve 
a saturation of peripheral oxygen (SpO2) between 92% 
and 96%50 unless otherwise specified by the attending 
anaesthetist/ICU consultant. Gas flow rate is set at 50 L 
per minute. If a participant is unable to tolerate this flow 
rate, it can be reduced to a minimum of 30 L per minute. 
High-flow nasal oxygen therapy is to be provided contin-
uously for 48 hours from the time of extubation. Changes 
to flow rate and any removal of high-flow nasal oxygen 
therapy for more than 15 min during the 48 hours period 
are recorded.
All other aspects of perioperative patient care, including 
the type of anaesthesia, postoperative analgesia, surgical 
techniques and postoperative clinical care are provided at 
the discretion of the anaesthesia and surgical teams and 
according to routine clinical practice at our centre. Prag-
matically, there will be no attempt to standardise perioper-
ative management or intraoperative ventilation strategies 
for this study. Our hospital is currently not recognised as 
an enhanced recovery after surgery (ERAS) site; however, 
some individual anaesthesia and surgical teams within 
our hospital adhere to ERAS principles.
Intervention group
Care is provided as per the control group above, with 
the exception of five 30 min11 NIV sessions delivered by 
a physiotherapist over the first two postoperative days in 
addition to high-flow nasal oxygen therapy. The initial 
NIV dose is delivered within 4 hours of extubation, 
followed by twice daily sessions on postoperative days 1 
and 2. This service is provided in the PACU, ICU/HDU 
or the surgical ward depending on the participant’s loca-
tion at the time of NIV delivery.
Prior to commencing each NIV session, all partici-
pants are assessed for absolute contraindications for NIV 
therapy by the treating physiotherapist (table 2). The NIV 
sessions are delivered using a ResMed VPAP machine 
(ResMed, Oxfordshire, UK) with a humidified circuit and 
standard face mask. This is delivered with participants 
either sitting up in bed with the bed head raised between 
45° and 90° or with the participant sitting out of bed in 
a high back chair. Expiratory positive airway pressure 
(EPAP) is set at 10 cmH2O.
11 Inspiratory positive airway
pressure (IPAP) is initially set at 15 cmH2O and adjusted 
as required to achieve tidal volumes of at least 6-8 mL/
kg. Participants with BMI >30 have a starting EPAP set at 
12 cmH2O and a starting IPAP set at 16cmH2O. Devia-
tions from these planned settings are reported and docu-
mented. The difference between IPAP and EPAP (known 
as pressure support ventilation (PSV)) is maintained at a 
minimum of 4 cmH2O, and the maximum total pressure 
(PSV+EPAP) will be no greater than 25 cmH2O.
11
If a participant is unable to tolerate the set pressures, 
reassurance is first given to the participant and the 
following modifications taken in sequential order, until 
patient tolerance is achieved:
1. Reduce EPAP to 8 cmH2O (set minimum).
2. Reduce IPAP to 12 cmH2O (set minimum) in decre-
ments of 1 cmH2O.
If the participant remains unable to tolerate the
therapy despite pressure titration and reassurance, cessa-
tion of NIV therapy will occur and be reported. Pressure 
rise time is set at the slowest speed (900 ms), and the 
inspiratory trigger is set to the minimum value. Air leaks 
are managed by fitting the correct size mask carefully 
using the mask measure guide provided by ResMed with 
focus on minimising leaks around the nasogastric tube 
if present. The ResMed VPAP compensates for air leaks 
up to 40 L per minute. Above this a ‘high-leak’ alarm 
sounds, and the machine is unable to deliver the set pres-
sure. Any high-leak alarm is monitored, recorded and 
the mask readjusted accordingly. Ideally, the duration 
of NIV is to be 30 min of continuous therapy; however, 
if NIV therapy needs to be temporarily stopped, therapy 
time will cease and reason will be documented. Once 
therapy is restarted, timing will recommence. If a partic-
ipant is unable to continue with NIV therapy within 
5 min of temporarily ceasing, the session is terminated 
and the reason documented. Supplemental oxygen is 
titrated through the ResMed VPAP as required to achieve 
SpO2 92%–96% unless otherwise specified by the medical 
team. During each NIV session, participants have their 
high-flow nasal oxygen therapy removed for the duration 
of NIV therapy and replaced once therapy is finished. The 
treating physiotherapist continuously monitors all partic-
ipants for the duration of the NIV therapy and reassesses 
30 min postintervention. Data including blood pressure, 
Table 3 Early postoperative ambulation protocol48
Stage 1 (safety)
Sit over edge of bed/sit in chair 
minimum of 2 min.
Stage 2 (safety) March on spot 0–1 min.
Stage 3 (ambulation) March on spot/walk away from 
bedside 1–3 min.
Stage 4 (ambulation) March on spot/walk away from 
bedside 3–6 min.
Stage 5 (ambulation) Walk away from bedside 6–10 min.
Stage 6 (ambulation) Walk away from bedside 10–15 min.
Stage 7 (ambulation) Walk away from bedside >15 min.
Protocol
Provide assisted early ambulation as soon as possible on the first 
postoperative day.
At each session progress through each stage in sequence. Time 
achieved in the session is accumulative.
Aim to achieve rating of perceived exertion of greater than 3/10.
Aim to assist patient to ambulate more than 10 min (stage 6 or 
greater).
Once patient able to ambulate past stage 3, patient can be 
assisted to ambulate with a physiotherapy assistant, as long as 
safe to do as determined by the ward physiotherapist.
Interval training is permissible to obtain target walking time. Each 
interval of rest time must not exceed the preceding work time. 
Total session time is the accumulative work time.
Provide assisted early ambulation once a day until discharged 
according to the discharge scoring tool.49
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heart rate, respiratory rate and SpO2are recorded before, 
immediately after and 30 min after each NIV session. Any 
reason resulting in early cessation of NIV intervention or 
being unable to provide NIV therapy is reported.
All physiotherapists providing the intervention attend 
NIV training with the ICU senior physiotherapist who 
has 11 years’ experience in NIV application. The training 
session includes familiarisation with the ResMed VPAP 
machine, setup of equipment, detailed explanation of 
the intervention protocol and troubleshooting. The phys-
iotherapists are provided with a training manual and a 
copy of this manual is also kept with the ResMed VPAP to 
allow reference at any point during the intervention. The 
training manual consists of all the information provided 
in the training session. The years of hospital experience 
of each participating physiotherapist is reported.
Withdrawal from trial
Participants are withdrawn for: (1) requiring longer than 
48 hours of mechanical ventilation following surgery, or 
(2) withdrawal of consent. All withdrawals are reported.
outcomes
To detect a possible signal towards PPC reduction with 
the use of NIV in addition to continuous high-flow oxygen 
therapy in the first 48 hours after surgery, the primary 
outcome measure is the development of a PPC within the 
first 14 postoperative days or hospital discharge whichever 
occurs first. Using the Melbourne Group Scale (MGS) 
diagnostic Tool Version 248 (box 1), a PPC is diagnosed 
when four or more of eight screening criteria are present 
in a 24-hour day. The MGS tool is valid and reliable,51 is 
sensitive to therapeutic interventions designed to amelio-
rate postoperative atelectasis and alveolar derecruit-
ment48 and widely utilised in upper abdominal surgery 
trials.4–6 48 An assessor blinded to group allocation, who 
has no clinical involvement with the study, assesses partic-
ipants prospectively and daily for a PPC until the seventh 
postoperative day. Thereafter, additional PPC assessments 
are only performed if clinically indicated when there are 
signs of respiratory deterioration reported in the medical 
record until postoperative day 14 or hospital discharge, 
whichever occurs first. To reduce the potential for missing 
data, retrospective collection of PPC data from the daily 
medical record will occur when a participant or assessor 
is unavailable for PPC assessment. Participants scoring 
three out of the possible eight factors are assessed twice 
daily to monitor for any further clinical deterioration. A 
blinded senior physiotherapist confirms a positive diag-
nosis of a PPC.
Feasibility measures of trial conduct, design and protocol
1. Consent and recruitment ability. Consent rate is an-
ticipated to be ≥90% with recruitment of one to two
patients per week.
2. Protocol adherence of physiotherapy-led NIV therapy.
Successful physiotherapy-led NIV implementation is
set at ≤20% protocol deviations. This is measured and
reported by:
a. Proportion of intervention participants who receive
the first NIV session within 4 hours of surgical extu-
bation.
b. Proportion of intervention participants who receive
five 30 min NIV sessions in the first two postopera-
tive days.
c. Reasons why NIV therapy could not be delivered or
were ceased early.
3. Protocol adherence of high-flow nasal oxygen therapy.
Successful high-flow nasal oxygen therapy implemen-
tation is set at <20% protocol deviations. This is mea-
sured and reported by;
a. Proportion of participants who receive high-flow na-
sal oxygen therapy for 48 continuous hours follow-
ing surgical extubation.
b. Time in minutes from extubation following surgery
to commencement of high-flow nasal oxygen ther-
apy.
c. Reasons why high-flow nasal oxygen therapy cannot
be delivered or sustained.
4. Safety of NIV therapy measured by: (1) major adverse
events relating to NIV therapy defined as: anastomot-
ic leak suspected and confirmed; severe hypotension
requiring an increase in medical management; cardi-
ac and/or respiratory arrest; deterioration in medical
condition requiring an increase in medical manage-
ment and (2) any transient physiological events during
or immediately following NIV intervention (table 2).
5. Costs of a high-flow nasal oxygen therapy and phys-
iotherapy-led NIV therapy service measured by: costs
of equipment (NIV masks, high-flow and NIV circuits,
cleaning and machine service costs); physiothera-
py time (in hours) attributed to delivering the NIV
box 1 Postoperative pulmonary complications diagnostic 
tool: Melbourne group scale version 248
Diagnosis confirmed when four or more of the following criteria are 
present anytime in the 24-hour period 00:01 to 24:00 on a single post-
operative day:
1. New abnormal breath sounds on auscultation different to preoper-
ative assessment.
2. Productive of yellow or green sputum different to preoperative
assessment.
3. Pulse oximetry oxygen saturation (SpO
2) <90% on room air on more
than one consecutive postoperative day.
4. Raised maximum oral temperature >38°C on more than one con-
secutive day.
5. An unexplained white cell count greater than 11×109/L.
6. Presence of infection on sputum culture report.
7. Chest radiograph (CXR) report of collapse/consolidation. When a
CXR has been taken but no report available, a ward medical officer
or a senior respiratory physiotherapist with more than 10 years' ex-
perience will be asked to report.
8. Physician’s diagnosis of pneumonia, lower or upper respiratory tract 
infection, an undefined chest infection or prescription of an antibiot-
ic for a respiratory infection.
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therapy and costs of an ICU; and hospital stay mea-
sured by average cost of a bed day.
secondary exploratory outcomes
1. Incidence of pneumonia52 defined as new chest ra-
diograph infiltrates with at least two of: tempera-
ture >38°C, dyspnoea , cough and purulent sputum,
altered respiratory auscultation and white cell count
(WCC) >12 000/mL or leucopaenia <3000/mL), with-
in the first 14 postoperative hospital days or hospital
discharge whichever occurs first.
2. Incidence of systemic inflammatory response syn-
drome (SIRS) as defined by two or more of the fol-
lowing: temperature >38 or <36; heart rate (HR) >90;
respiratory rate (RR) >20 or Partial  pressure of car-
bon  dioxide in arterial  blood (PaCO2) <32, or ventila-
tion for acute process; WCC >12 or <4, within the first
14 postoperative hospital days or hospital discharge,
whichever occurs first.
3. Incidence of sepsis, defined as a Sequential Organ
Failure Assessment score ≥2, within the first 14 postop-
erative hospital days or hospital discharge, whichever
occurs first.
4. Postsurgical ICU and hospital LOS in days.
5. Unplanned ICU admission at any time-point during
the acute postsurgical stay.
6. Incidence of reintubation at any time-point during the
acute postsurgical stay.
7. In-hospital, 30-day and 12-month mortality.
8. HRQoL using the EQ-5D-5L53 preoperatively, postoper-
ative day 7 and day 14 and at 12 months postoperatively.
blinding
Random allocation occurs following completion of 
surgery. This ensures preadmission and operating theatre 
medical, nursing and physiotherapy staff are masked to 
postoperative group assignment. Postoperatively, PPC 
assessors are independent of routine postoperative clin-
ical care and masked to group allocation. All physio-
therapy documentations relating to the NIV intervention 
are documented and filed separately to ensure PPC asses-
sors remain blinded for the first seven postoperative days 
and then added to the patient’s medical file. If a treat-
ment group participant informs the PPC assessor of their 
group allocation, this is noted and reported. Due to the 
nature of intervention, postoperative ward staff including 
nurses, doctors and treating physiotherapists are unable 
to be blinded.
data collection
Preoperative variables
To measure baseline characteristics, the following vari-
ables are collected directly from the participant or the 
medical record: age (years), gender, height (cm), weight 
(kg), body mass index (kg/cm2), planned surgical 
procedure, surgical category and reason for the proce-
dure, physical health status according to the American 
Society of Anaesthesiologists and rated by the attending 
anaesthetist at the pre-admission clinic (PAC) (score 
1–5), smoking history (non-smoker, current smoker or 
ex-smoker having ceased more than 8 weeks preopera-
tively), smoking pack years (one pack year=20 cigarettes 
per day for 1 year), years since smoking cessation, respi-
ratory status including auscultation signs and SpO2 (%) 
on room air, cough strength and presence of sputum, 
participant-reported history of a chest infection in the 
previous 2 weeks, functional comorbidity index,54 partic-
ipant-reported estimated maximum metabolic equivalent 
physical activity using a self-rated physical Specific Activity 
Questionnaire55 and any limiting factor to ambulation.
Intraoperative variables
The following variables are collected from the anaesthetic 
record, operation report and medical record: duration 
of anaesthesia (in minutes) during surgery; mechanical 
ventilation parameters including mode of ventilation, 
level of pressure/volume control, positive end expira-
tory pressure used and any recruitment manoeuvres 
performed; average FiO2 during surgery; type and amount 
of intraoperative fluid delivered (mL/kg/hour); number 
and type of blood transfusion units; and incision type.
Postoperative variables
Postoperative data are collected daily for the first 14 days 
or until hospital discharge, whichever occurs first for the 
following variables: time in days from the preoperative 
physiotherapy session to the operation; location (ICU 
or surgical ward) and duration in days at each location; 
duration of analgesia and type (epidural, constant opioid 
infusion, patient controlled analgesia, patient controlled 
epidural analgesia, oral, local pain infusion or other); 
unplanned ICU admission and ICU LOS; hospital LOS; 
hours of mechanical ventilation; days of vasopressor 
use; days and types of oxygen therapy use; total days of 
nasogastric tube; and day and diagnosis of a prolonged 
postoperative ileus using a standardised criteria56 of two 
or more of the following factors in a 24-hour period 
including nausea/vomiting, inability to tolerate normal 
diet, absence of flatus, abdominal distension, radiologic 
confirmation and physician diagnosis of ileus. Postop-
erative NIV parameters are collected including: time 
in hours from extubation following surgery to the first 
NIV session; time each NIV session is delivered and the 
grade/seniority of the treating physiotherapist providing 
the NIV; position of the patient during NIV; duration in 
minutes of each NIV session; IPAP and EPAP used; pres-
sure titration—reasons if pressure titration occurs and the 
pressures used; number of times NIV has to temporarily 
ceased prior to the planned 30 min session; reasons NIV 
was unable to be delivered to the participant; and any 
major adverse or transient physiological event that occurs 
as a direct result of NIV therapy. Postoperative high-flow 
nasal oxygen therapy parameters are collected including: 
time in minutes from extubation following surgery onto 
high-flow nasal oxygen therapy; time and date high-flow 
nasal oxygen therapy is removed; duration in hours of 
11Lockstone J, et al. BMJ Open 2019;9:e023139. doi:10.1136/bmjopen-2018-023139
Open access
high-flow nasal oxygen therapy within the first 48 post-
operative hours; number of times high-flow nasal oxygen 
therapy is removed for greater than 15 min within the first 
two postoperative days; average flow rate during the first 
two postoperative days; average FiO2 during the first two 
postoperative days; and reasons a participant is unable 
to have postoperative high-flow nasal oxygen therapy 
for the first two postoperative days. Early ambulation 
parameters are collected including: time in hours from 
end of surgery until time to ambulation >1 min; postop-
erative day walked longer than 10 min; maximum rating 
of perceived exertion during ambulation at each session; 
and maximum ambulation stage attained at each session 
and reasons for a participant being unable to participate 
in an ambulation session.
sample size
This RCT is a pilot trial that has been funded to be 
conducted for a defined time period (18 months). 
Current surgical throughput of eligible patients at our 
hospital predicts that we will recruit a sample of 130 
eligible participants (65 per group) in the trial period. If 
this sample is not reached within the funded time period, 
recruitment will continue until a minimum sample of 130 
is met. If this sample is reached prior to the designated 
funding period (18 months), recruitment will continue 
past 130, until this time period is completed. A baseline 
PPC rate of 18% for the control group (high-flow nasal 
oxygen therapy alone) is anticipated based on historical 
Lung Infection Prevention Post Surgery - Major Abdom-
inal - with Pre-Operative Physiotherapy trial (LIPPSMAck 
POP)48 data (n=101) of matched high-risk elective upper 
abdominal surgery participants who were given the same 
standardised preoperative and postoperative physio-
therapy as planned in NIPPER PLUS.
Previous systematic reviews in NIV to prevent pneu-
monia following surgery report a relative risk reduction 
of approximately 60%.14 57 Using inference for propor-
tion calculations for two independent samples, a total 
sample of 130 (two groups of 65) would detect a 50% rela-
tive risk reduction in PPC between groups (favouring the 
NIV group, one-sided alpha at 0.05) with only 44% power. 
This sample will only be adequately powered (80%) if 
there is a large 75% relative risk reduction in PPC with 
the application of NIV (18% down to 4%).
Assuming that NIV is superior to high-flow nasal 
oxygen therapy, an adequately powered study would need 
a sample of at least 450 (relative risk reduction 50% from 
a baseline of 18%, alpha two-sided 0.05, beta 80%) which 
would require a multicentre approach. However, there is 
also the possibility that high-flow nasal oxygen therapy is 
just as effective as NIV to prevent PPC. This would require 
a non-inferiority trial and would require a much larger 
sample.
This pilot study aims to measure the feasibility of the 
intervention protocol and provide a baseline estimate of 
effect to assist in determining the design (superiority or 
non-inferiority) and conduct of a future multicentre RCT.
Methods: data collection, management and analysis
Data are collected from participants using a standardised 
electronic case report form and stored on a password-pro-
tected electronic hard drive. Research assistants and site 
investigators responsible for data collection are trained 
directly by the principal investigator to ensure correct data 
handling. Any data or participant lost to follow-up will be 
reported. Once each participant’s data set is completed, 
it is deidentified, entered into a main database, locked 
and maintained securely by the principal investigator. 
All data, consent forms and relevant correspondence are 
stored according to Australian privacy laws and archived 
for a minimum of 12 years. On completion of the trial, the 
database will be made available for independent analysis 
or as an appendix in the publishing journal if requested.
statistical methods
As our study is stratified to postoperative location (ICU/
ward) only, there is a possibility of significant base-
line differences between groups. This will be managed 
according to the prognostic strength and size of imbal-
ances due to potential confounding baseline variables 
between groups being assessed.58 Adjustment covariates 
will be selected by backward stepwise regression from 
covariates that may have the potential for clinically signif-
icant alterations in effect sizes. These include: smoking 
history, age, length in time of operation, operation cate-
gory (upper gastrointestinal, colorectal, urological and 
other), incision type and location,59 intraoperative venti-
lation strategies,3 60 fluid delivery,61 blood transfusions62 
and mode of postoperative analgesia.63
The primary outcomes of absolute and relative rates 
of PPC in the trial groups will be estimated using multi-
variate robust random effects Poisson generalised linear 
modelling to allow assessment of binary outcomes with or 
without adjustment for potential confounding variables 
(incidence rates and rate ratios, 95% CIs and p values). 
In addition, the effect of time from the end of surgery/
anaesthesia to diagnosis of PPC will be compared using 
Cox proportional hazards regression with and without 
covariate adjustment (HR, 95% CIs and p values). 
Graphic representation of this analysis will be performed 
using the Kaplan-Meier method.
Although this study is not adequately powered, a 
number of secondary outcomes will be treated as time-to-
event analyses, with HRs estimated using Cox proportional 
hazards regression: (1) the day of first diagnosis of other 
events will be recorded (pneumonia, SIRS, sepsis, reintu-
bation and death) and (2) treatment group comparison 
for time from surgery to readiness for discharge, and to 
actual discharge (LOS), will be made using Cox propor-
tional hazards regression, with successful discharge 
treated as censoring ‘failure’ and death or no discharge 
within 30 days treated as censoring ‘non-failure’. Bino-
mial secondary outcomes including unplanned ICU 
admission, unplanned reintubation will be analysed 
using mixed effects Poisson regression. Secondary 
outcomes with irregular distributions, including length 
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of time periods (ICU and total postoperative LOS) and 
HRQoL, will be evaluated for group differences using 
mixed effects ordered logistic regression, with mean time 
(95 % CI) estimated for descriptive purposes using mixed 
effects linear regression. An intention-to-protocol sensi-
tivity analysis will be performed by excluding from the 
analysis any participant who did not undergo the planned 
postoperative NIV intervention treatment. The sensitivity 
of the outcome estimates to missing data will be evaluated 
using multiple imputation. All analyses will be performed 
using Stata V.14 or later and analysed on an intention-to-
treat basis.
Methods: monitoring
Data monitoring
The steering committee consists of the principal inves-
tigator, local investigator and two academic supervi-
sors who contribute to the design and revision of this 
study protocol. The principal and local investigators are 
responsible for the study administrative management and 
daily coordination of the trial ensuring appropriate trial 
conduct, record keeping and data management.
An independent Data and Safety Monitoring Board 
(DSMB) monitors the ethics of the study in accordance 
with the Declaration of Helsinki overseeing safety and 
conduct of the study.
For the trial, there is a stopping rule for the potential 
of NIV or high-flow nasal oxygen therapy to be harmful. 
An unacceptable rate of anastomotic leakage of over 
2.5% will trigger consideration for trial termination by 
the independent DSMB established for the oversight of 
this clinical trial. To detect a 2.5% anastomotic leakage 
rate in either group requires a minimum of 57 patients 
(one-sample test of proportion compared with hypothet-
ical 0.1% rate; power 80%; alpha 0.05). Analysis of anasto-
motic leakage rates only in both groups will therefore be 
performed at participant recruitment number 60 using 
cumulative summation analysis.64
Any other major adverse events directly relating to the 
interventions will be reported with oversight from the 
independent DSMB.
Ethics and dissemination
Trial results will be disseminated widely through confer-
ence presentations and peer-review journal publications.
dIsCussIon
Consequences of PPCs following upper abdominal 
surgery are well defined, leading to great interest in their 
prevention. High-risk patients have been shown to be over 
eight times more likely to develop a PPC compared with 
individuals identified as low-risk6 suggesting increased 
attention is required to improve postoperative outcomes 
in this high-risk cohort.
While previous clinical studies support the use of 
preventative NIV therapy following major abdominal 
surgery,11 14 17 implementation of NIV therapy does not 
appear to be standard postoperative care4 21 and a number 
of important methodological limitations exists in previous 
literature including high-bias risk and minimal reporting 
of adverse events.14 Recommendations for future 
research include; evaluating the use of NIV in preventing 
mortality, a targeted approach investigating patients 
at higher risk for PPCs and must report on all adverse 
effects and possible complications of preventative postop-
erative NIV.14 17 The NIPPER PLUS study is designed to 
begin targeting these recommendations by collecting and 
reporting on in-hospital, 30-day and 12-month all-cause 
mortality for all participants and is recruiting participants 
identified as high-risk of developing a PPC only. High risk 
for this study has been defined as either: eligible patients 
with a planned postoperative admission to ICU/HDU 
due to this factor being independently associated with 
the development of a PPC6 or eligible patients identified 
at high risk using the MRPT.6 The MRPT has been shown 
to be specific and sensitive in the identification of indi-
viduals who are at highest risk of PPC development in the 
surgical settings including upper abdominal surgery.5 6
Preventative NIV was associated with no major complica-
tions in our observational study,41 and the NIPPER PLUS 
trial aims to further support this finding by reporting on 
any adverse event as well as transient physiological events 
directly relating to NIV therapy during, immediately 
following and 30 minutes after therapy, therefore contrib-
uting to necessary and strongly recommended NIV safety 
data for both ICU and ward patients.
All previous preventative NIV clinical trials in abdom-
inal surgery compare NIV with standard oxygen therapy 
only14 17; however, the application of high-flow nasal 
oxygen therapy is becoming widespread in ICUs40 and 
in other clinical settings.26 The NIPPER PLUS study is 
designed with high-flow nasal oxygen therapy as standard 
care to match current clinical practice within our ICU 
unit and aims to detect whether there is a possible signal 
towards PPC reduction with the use of additional inter-
mittent NIV compared with continuous high-flow oxygen 
therapy alone. The NIPPER PLUS trial is a single-centre 
study. The effect of high-flow nasal oxygen therapy in 
high-risk upper abdominal surgery patients is currently 
unclear. Prior to undertaking expensive fully powered 
multicentre trials, there is a need to build evidence and 
data from pilot trials for realistic effect size variability 
estimation and to measure the design, feasibility, safety 
and potential challenges of treatment protocols. This 
pilot study aims to inform future definitive trial design 
and conduct. Interpretation of results will be evaluated 
in context of the studies’ limitations and indeed it may be 
demonstrated that this protocol is unfeasible in its current 
form and would be futile to progress to multicentre trials 
without study and protocol redesign.
In conclusion, the NIPPER PLUS trial is a single-centre, 
assessor-blinded, parallel group, pilot RCT, which aims 
to detect whether there is a possible signal towards PPC 
reduction with the use of additional intermittent NIV 
compared with continuous high-flow oxygen therapy 
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alone following high-risk elective upper abdominal 
surgery. This trial is measuring recruitment ability, feasi-
bility of implementing a physiotherapy-led NIV and high-
flow nasal oxygen therapy protocol, safety of NIV therapy 
and preliminary costs of care information on a NIV and 
high-flow nasal oxygen therapy service. This will assist 
in the design and conduct of future multicentre trials. 
In addition, this trial will also explore possible effects 
on postsurgical ICU and hospital LOS, unplanned ICU 
admission, reintubation rates, in-hospital, 30-day and 
12-month mortality. This trial standardises preoperative
and postoperative physiotherapy care and is currently 
recruiting.
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